PYXS Pyxis Oncology
- 4.300
- 0.0000.00%
- 4.300
- 0.0000.00%
Pyxis Oncology News
HROW, HCAT and EGRX Are Among After Hour Movers
Buy Rating Affirmed for Pyxis Oncology as PYX-201 Showcases Promising Preclinical Data and Broad Therapeutic Potential
Analyst Swayampakula Ramakanth of H.C. Wainwright maintained a Buy rating on Pyxis Oncology (PYXS – Research Report), retaining the price target of $7.00.
HC Wainwright & Co. : Pyxis Oncology (PYXS.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $7.00.
HC Wainwright & Co. : Pyxis Oncology (PYXS.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $7.00.
HC Wainwright & Co. Reiterates Buy on Pyxis Oncology, Maintains $7 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ:PYXS) with a Buy and maintains $7 price target.
Signet Jewelers, Dave & Buster's Entertainment, Blue Owl Capital And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones gaining over 50 points on Wednesday. Shares of Signet Jewelers Limited (NYSE:SIG) rose sharply during Wednesday's session after the company raised its FY25
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, reported today that Pyxis
Analysts Offer Insights on Healthcare Companies: Aura Biosciences Inc (AURA), Spectral AI (MDAI) and Pyxis Oncology (PYXS)
Pyxis Oncology Files to Sell 10.46M Common Shares for Holders
Pyxis Oncology Completed The Sale Of Its Rights To Royalties From The Commercialization Of Beovu (Brolucizumab-dbll) And Another Asset To Novartis For $8M
Pyxis Oncology Completed The Sale Of Its Rights To Royalties From The Commercialization Of Beovu (Brolucizumab-dbll) And Another Asset To Novartis For $8M
Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights
Non-dilutive funding to support development of first-in-concept lead Antibody-Drug Conjugate (ADC) asset, PYX-201 Pyxis Oncology retains rights to three other antibodies in development by Apexigen's licensees discovered
Optimistic Buy Rating for Pyxis Oncology's PYX-201 Based on Strong Safety Profile and Promising Therapeutic Potential
Insiders Who Sold Pyxis Oncology Made The Right Call As Market Cap Slides By US$50m
By selling US$81k worth of Pyxis Oncology, Inc. (NASDAQ:PYXS) stock at an average sell price of US$2.23 over the last year, insiders seemed to have made the most of their holdings. The company's mark
Pyxis Oncology Price Target Maintained With a $7.00/Share by RBC Capital
Pyxis Oncology Price Target Maintained With a $7.00/Share by RBC Capital
Pyxis Oncology (PYXS) Gets a Buy From RBC Capital
Pyxis Oncology Is Maintained at Buy by HC Wainwright & Co.
Pyxis Oncology Is Maintained at Buy by HC Wainwright & Co.
Buy Rating on Pyxis Oncology: Promising PYX-201's Safety Profile and Strategic Focus on Solid Tumors
HC Wainwright & Co. Maintains Buy on Pyxis Oncology, Raises Price Target to $7
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Pyxis Oncology with a Buy and raises the price target from $4 to $7.
Pyxis Oncology Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/22/2024 59.82% HC Wainwright & Co. $4 → $7 Maintains Buy 02/09/2024 82.65% BTIG → $8 Initiates Coverage
Buy Rating Affirmed: Pyxis Oncology's Financial Health and Promising Drug Candidate PYX-201 Bolster Optimism
Health Care Up on Drug Sales Optimism -- Health Care Roundup
Health-care companies rose amid optimism about pharmaceutical sales. Shares of Pyxis Oncology fell sharply after the cancer drug developer said it would likely harvest initial data from its lead prog
Analysis
Price Target
No Data
